MedTrace Logo

Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity

NCT02372318 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-07-02

No results posted yet for this study

Summary

The aim of this study is to use functional Magnetic Resonance Imaging (fMRI) to measure neural reactivity to alcohol-related and emotional cues in alcohol dependent subjects following a single dose of the opioid receptor modulator nalmefene. The study will be done in a cross over design with nalmefene versus placebo.

Conditions

  • Alcoholism

Interventions

DRUG

Nalmefene

18mg of Nalmefen will be administered orally

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • Lundbeck GmbH, Ericusspitze 2, 20457 Hamburg

    collaborator UNKNOWN

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • Sabine Vollstädt-Klein, Prof. Dr. · Central Institute of Mental Health, Mannheim

  • Falk Kiefer, Prof. Dr. · Central Institute of Mental Health, Mannheim

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02372318 on ClinicalTrials.gov